Dec. 6, 2021 Price forecast | 2 weeks: 4.32% | 1 month: 1.92% | 3 months: 12.25% | Premium Forecast


OTLK stock forecast

Our latest prediction for Outlook Therapeutics Inc's stock price was made on the Dec. 6, 2021 when the stock price was at 1.37$.

In the short term (2weeks), OTLK's stock price should outperform the market by 4.32%. During that period the price should oscillate between -11.14% and +25.89%.

In the medium term (3months), OTLK's stock price should outperform the market by 12.25%. During that period the price should oscillate between -48.03% and +60.66%.

Create a solid portfolio with OTLK

Add OTLK to your portfolio and optimize it!


About Outlook Therapeutics Inc

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.

At the moment the company generates 8M USD in revenues.

On its last earning announcement, the company reported a loss of -0.25$ per share.

The book value per share is -0.23$

Outlook Therapeutics Inc website


Three months stock forecastDec. 6, 2021


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
8M - -48M -307.20% -50M -0.25 - - 141M -0.23 -57M - -57M